Is it true that Higher doses of Mirtazapine always cause more sedation.?

Lower doses of Mirtazapine (e.g., 15 mg) are often more sedating than higher doses (e.g., 45 mg) due to stronger H1 antagonism at lower concentrations.

Is it true that All antidepressants require routine laboratory monitoring.?

Most antidepressants do not require routine labs; monitoring is based on clinical indication, specific drug risks (e.g., LFTs for Duloxetine/Nefazodone, ECG for Citalopram/TCAs), or patient factors (e.g., weight, BP).

PMHNP Antidepressant Master Cheat Sheet

Antidepressants are not one-size-fits-all; selection requires a trade-off analysis considering patient-specific symptoms, tolerability, medical conditions, interactions, overdose risk, adherence, and speed of improvement, with a crucial initial screen for bipolar disorder.

Core Principles

Universal Antidepressant Rules: Always screen for bipolar disorder, suicide risk, psychosis, substance use, pregnancy/lactation, drug interactions, baseline vitals, QT/seizure risk, and serotonergic polypharmacy before initiating treatment.
SSRI Differentiators: Memorize FDA indications for Fluoxetine (Bulimia), Sertraline (Anxiety Spectrum), Escitalopram (MDD/GAD), Citalopram (QT risk), Paroxetine (Withdrawal/Sedation), and Fluvoxamine (OCD/Interactions).
SNRI Pearls: Venlafaxine requires BP/HR monitoring and has high withdrawal risk; Duloxetine is indicated for pain (neuropathy, fibromyalgia).
Bupropion Profile: Choose for activating effects, weight neutrality/loss, and sexual side effect friendliness, but avoid in seizure disorders or eating disorders.
Mirtazapine's Niche: Effective for depression with insomnia and appetite loss due to sedation and appetite stimulation, with lower doses being more sedating.
TCA Dangers: Extremely effective but lethal in overdose; monitor for anticholinergic effects, orthostasis, sedation, weight gain, and cardiac conduction delays. Sodium bicarbonate is key in overdose.
MAOI Caution: Requires strict adherence to washout periods (14 days for most, 5 weeks for fluoxetine) to avoid serotonin syndrome and hypertensive crisis (especially with tyramine).

Action Steps

Screen for bipolar disorder, suicide risk, psychosis, substance use, pregnancy/lactation, drug interactions, baseline weight/BP/HR, QT risk, seizure risk, and serotonergic polypharmacy before starting any antidepressant.
For SSRIs, differentiate based on FDA indications: Fluoxetine for bulimia, Sertraline for anxiety spectrum, Escitalopram for MDD/GAD, Citalopram with QT risk awareness, Paroxetine for withdrawal/sedation, and Fluvoxamine for OCD.
Monitor BP and HR for Venlafaxine due to withdrawal and BP risks.
Consider Duloxetine for patients with comorbid neuropathic pain or fibromyalgia.
Avoid Bupropion in patients with seizure disorders, current/past bulimia or anorexia nervosa, or abrupt withdrawal from alcohol/benzodiazepines/barbiturates.
Monitor weight, lipids, and glucose for Mirtazapine if significant weight gain occurs.
In TCA overdose, administer sodium bicarbonate.
Adhere to MAOI washout periods: 14 days when switching to/from most antidepressants, and 5 weeks when switching from fluoxetine.
Administer Esketamine in a monitored setting and assess BP, sedation, and dissociation.
Instruct patients taking Zuranolone not to drive for at least 12 hours after each dose due to sedation risk.

Key Terms

SSRI: Selective Serotonin Reuptake Inhibitor; first-line antidepressants often used for MDD, anxiety disorders, and OCD.
SNRI: Serotonin-Norepinephrine Reuptake Inhibitor; effective for MDD, GAD, and pain conditions.
NDRI: Norepinephrine-Dopamine Reuptake Inhibitor (e.g., Bupropion); known for activating effects and fewer sexual side effects.
NaSSA: Noradrenergic and Specific Serotonergic Antidepressant (e.g., Mirtazapine); useful for insomnia and appetite stimulation.
SARI: Serotonin Antagonist and Reuptake Inhibitor (e.g., Trazodone, Nefazodone); often used for insomnia or depression, with Trazodone's unique risk of priapism and Nefazodone's hepatotoxicity.
TCA: Tricyclic Antidepressant; highly effective but associated with significant side effects and dangerous overdose potential.
MAOI: Monoamine Oxidase Inhibitor; potent antidepressants used for treatment-resistant depression, requiring strict dietary and drug interaction precautions.
NMDA antagonist: N-methyl-D-aspartate antagonist (e.g., Esketamine); rapid-acting antidepressants administered in monitored settings, associated with dissociation and BP elevation.
GABA-A positive allosteric modulator: Neuroactive steroids (e.g., Brexanolone, Zuranolone) that enhance GABA-A receptor activity; used for postpartum depression, with risks of sedation and cognitive impairment.
Discontinuation Syndrome: Symptoms (FINISH: Flu-like, Insomnia, Nausea, Irritability, Sensory disturbances, Hyperarousal) that can occur upon abrupt cessation of antidepressants, especially those with short half-lives like Paroxetine and Venlafaxine.
Serotonin Syndrome: A potentially life-threatening condition caused by excessive serotonergic activity, characterized by mental status changes, autonomic instability, and neuromuscular abnormalities.
QT Prolongation: Lengthening of the QT interval on an electrocardiogram, increasing the risk of potentially fatal arrhythmias; a significant concern with Citalopram and TCAs.
CYP450 Interactions: Metabolic pathways in the liver (e.g., CYP2D6, CYP3A4) that can be inhibited or induced by antidepressants, affecting the concentration of other medications.

Pro Tips

Fluoxetine's long half-life makes it the easiest SSRI to discontinue and useful when adherence is poor, as it self-tapers pharmacokinetically.
Lower doses of Mirtazapine are often MORE sedating due to stronger H1 antagonism.
Trazodone is more commonly used off-label for insomnia (25-100 mg HS) than as a primary antidepressant.
For older adults on TCAs, be vigilant for anticholinergic burden, falls, cognitive impairment, orthostasis, and cardiac conduction.
At the lowest Selegiline transdermal (EMSAM) dose (6 mg/24h), dietary tyramine restriction is less critical.
When an SSRI causes sexual dysfunction, consider switching to Bupropion, Vortioxetine, or Mirtazapine, or augmenting with Bupropion.

Pitfalls to Avoid

Skipping the bipolar disorder screen before antidepressant monotherapy can precipitate mania/hypomania.
Exceeding 40 mg/day of Citalopram increases QT prolongation risk significantly.
Abruptly discontinuing Paroxetine or Venlafaxine leads to high risk of severe discontinuation symptoms.
Using Bupropion in patients with seizure disorders or eating disorders can be fatal.
Nefazodone carries a risk of rare but potentially fatal hepatic failure.
Ignoring MAOI interactions with tyramine or serotonergic agents can cause hypertensive crisis or serotonin syndrome.
Failure to monitor BP before and after Esketamine administration can lead to dangerous BP elevations.

Myth vs Reality

Higher doses of Mirtazapine always cause more sedation.: Lower doses of Mirtazapine (e.g., 15 mg) are often more sedating than higher doses (e.g., 45 mg) due to stronger H1 antagonism at lower concentrations.
All antidepressants require routine laboratory monitoring.: Most antidepressants do not require routine labs; monitoring is based on clinical indication, specific drug risks (e.g., LFTs for Duloxetine/Nefazodone, ECG for Citalopram/TCAs), or patient factors (e.g., weight, BP).

Real World Examples

Patient with MDD, fatigue, and low motivation, with concerns about weight gain and sexual side effects.: Consider Bupropion (activating, weight neutral/loss, sexual side effect friendly).
Patient with MDD and significant insomnia and low appetite.: Consider Mirtazapine (sedating, stimulates appetite).
Patient with MDD and comorbid diabetic peripheral neuropathic pain.: Consider Duloxetine (indicated for both depression and neuropathic pain).
Patient with MDD who has failed multiple SSRIs and SNRIs.: Consider Esketamine for rapid response or Clomipramine for refractory OCD symptoms.
Patient with Postpartum Depression requiring rapid oral treatment.: Consider Zuranolone (14-day course, take with fat-containing meal, avoid driving for 12 hours post-dose).

Statistics

Increased suicide risk with conventional antidepressants (ages <24): Approx. 14 additional cases/1,000 in patients <18 and 5 additional cases/1,000 in ages 18–24 vs. placebo.
Citalopram max dose for certain populations: 20 mg/day if >60, hepatic impairment, or CYP2C19 poor metabolizer due to QT prolongation risk.
Desvenlafaxine recommended dose: 50 mg/day is both starting and therapeutic dose; higher doses showed no additional benefit.
MAOI washout period (MAOI to most antidepressants): 14 days
MAOI washout period (Fluoxetine to MAOI): 5 weeks due to fluoxetine's long half-life.
Zuranolone treatment duration: 50 mg PO nightly × 14 days